

Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight

<https://marketpublishers.com/r/GBAF6089CA3EN.html>

Date: August 2016

Pages: 660

Price: US\$ 2,400.00 (Single User License)

ID: GBAF6089CA3EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Cancer is ever fastest growing global epidemic and one of the leading causes of death in the developed countries. It was observed that year 2015 alone witnessed more than 10 million new cancer cases. The number of new cancer cases is predicted to rise to 22 million within the next two decades. More than 60 percent of the world's new cancer cases occur in Africa, Asia, and Central and South America; 70 percent of the world's cancer deaths also occur in these regions. The future burden will probably be even larger because of the adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and fewer childbirths, in economically developing countries.

Owing to this, the cancer segment of pharmaceutical industry is most studied and highly competitive in nature. The chemotherapeutic products are extremely diverse ranging from monoclonal antibodies, vaccines, immunomodulators, and hormonal therapies to bispecific monoclonal antibodies including the miscellaneous drugs. All the aforementioned drugs are formulated in a way to be step ahead in targeted approach from their predecessor. Nevertheless, all the above mentioned therapies have their own limitations; either they should be given in conjunction with other therapies, require high dose or have got enormous side effects and so on. They too have different pharmacological parameters, overlapping boundaries and cost effectiveness.

One of the major segments of cancer therapy is occupied by the angiogenesis inhibitors. The market for angiogenesis inhibitors is quiet optimistic as they have emerged as the new targeted therapy for the cancer treatment. These molecules due their specificity are gaining a lot of manufacturer's interest. With advent of new and improved technology, angiogenesis inhibitors therapy witnessed a drastic transition and

is becoming more acceptable due to its site specific approach. They have become a critical component of clinical treatment procedure for a variety of indications.

Angiogenesis is an important hallmark of tumor development. Hence, targeting angiogenesis is for sure help to eradicate the cancer. Similarly, metastasis is now a validated target for cancer treatment, the overall benefits of anti-angiogenic drugs from the perspective of impacting survival have left much to desire, endorsing a need for developing more effective therapeutic regimens. The anti angiogenic drugs are being combined with established conventional chemotherapeutic drugs to produce the desirable effect. There are now several agents available in the market such as bevacizumab that target the tumor vasculature through different pathways, either by inhibiting formation of the tumor neovasculature or by directly targeting the mature tumor vessels.

Although it has been found that their effects are compounded by their synergistic use with conventional chemotherapy rather than individual agents. For instance, an antiangiogenic drug such as bevacizumab is potent enough to bring about a transient functional normalization of the tumor vasculature. So, in order to get the maximum results out of it; this can be co-administered with chemo/radiotherapy.

Therapeutic innovations in various segments have made the transition from human conception to clinical reality over the past two decades and reached from labs to bedside of the patients. Now, many of angiogenesis inhibitors are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. Although majorly angiogenesis inhibitors are used as supportive therapy rather than streamline drugs as they take huge time to even show reasonable results. The market is no doubt flourishing and is sure to increase many folds as with due acceptance of clinicians and patients due to their targeted effect.

In future, the information drawn from genome medical science and genome-informatics that clearly identifies the disease centric antigens valuable for medical treatment is being employed to develop the therapy using mAbs. Currently, the more attention is getting paid toward targeted therapy. Several angiogenesis inhibitors, alone and in combination with other conventional therapies, are being tested in phase I and phase II clinical trials at the moment. The health market in coming years is sure to get loaded with BsAbs with prior approval of these prospective drugs.

Hence, it is quiet predictable that global market for angiogenesis inhibitors for cancer treatment is expected to register a healthy annual market growth rate during the

forecast period. The healthy growth rate can be related to the cumulative effects such as fast technological development, upsurge in the number of incidences of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.

“Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight” Report Highlights:

Angiogenesis Inhibitors: Introduction & Need in Cancer Therapy

Modulators & Mechanism of Angiogenesis

Classification of Angiogenesis Inhibitors

Metronomic Therapy - A Recent Advancement in Anti-Angiogenesis Therapy

Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Company, Indication & Phase

Global Cancer Angiogenesis Inhibitors Clinical Pipeline: 146 Drugs

Marketed Cancer Angiogenesis Inhibitors Drugs: 11 Drugs

Contents

1. ANGIOGENESIS: HISTORY AND QUEST FOR TREATMENT

2. ANGIOGENESIS INHIBITORS: AN OUNCE OF CURE & PREVENTION

2.1 Hallmarks of Cancer

- 2.1.1 Self Sufficiency in Growth Signals
- 2.1.2 Insensitivity to Antigrowth Signals
- 2.1.3 Acquired Capability: Evading Apoptosis
- 2.1.4 Limitless Replicative Potential
- 2.1.5 Sustained Angiogenesis
- 2.1.6 Tissue Invasion & Metastasis

2.2 Angiogenic- Metastatic Pathway as a Target for Anti-Cancer Therapies

3. WHAT IS ANGIOGENESIS?

3.1 Stages of Angiogenesis

3.2 Types of Angiogenesis

- 3.2.1 Sprouting Angiogenesis
- 3.2.2 Intussusceptive Angiogenesis or Splitting Angiogenesis

4. MODULATORS OF ANGIOGENESIS

4.1 VEGF & Angiogenesis

4.2 Platelet Derived Growth Factor

4.3 Fibroblast Growth Factors (FGFs) & FGF Receptors

4.4 Endothelins & Endothelin Receptors

4.5 Erythropoietin & Erythropoietin Receptor

4.6 Angiopoietins & Tie2 Receptor

5. MECHANISM OF ANGIOGENESIS

5.1 Dilation of Existing Vessels, Increase in Vascular Permeability & Degradation of Existing Vessels

5.2 Endothelial Cells Proliferation & Migration

5.3 Assembling of Endothelial Cells, Formation of Cords & Lumen

5.4 Long-Term Survival of Vascular Endothelium

5.5 Differentiation of Vascular Endothelium to Meet Local Needs

6. CLASSIFICATION OF ANGIOGENESIS INHIBITORS

- 6.1 Direct Endogenous Inhibitors of Angiogenesis
- 6.2 Indirect Inhibitors of Angiogenesis
- 6.3 Conventional Chemotherapeutic Agents
- 6.4 VEGF Targeted Therapy
- 6.5 FGF Targeted Therapies
- 6.6 Oncogene Targeted Therapy
- 6.7 Matrix Degrading & Remodeling Targeted Therapy
- 6.8 Stromal Tumor Associated Cell Targeted Therapy
- 6.9 Cell Adhesion Molecules (CAMs) Targeted Therapy
- 6.10 Inflammatory Angiogenesis Targeted Therapy

7. METRONOMIC THERAPY - A RECENT ADVANCEMENT IN ANTI-ANGIOGENESIS THERAPY

8. APPLICATIONS OF ANGIOGENESIS INHIBITORS

- 8.1 Quantitation & Prognosis of Malignant Disorders
- 8.2 Antiangiogenic Therapies
 - 8.2.1 Cancer
 - 8.2.2 Interferon Alpha-2 β to Treat Hemangiomas
 - 8.2.3 Ocular Neovascularization

9. GLOBAL ANGIOGENESIS INHIBITORS MARKET OVERVIEW

- 9.1 Current Market Scenario
- 9.2 Global Cancer Angiogenesis Inhibitors Clinical Pipeline Overview

10. GLOBAL CANCER ANGIOGENESIS INHIBITORS MARKET DYNAMICS

- 10.1 Favorable Market Parameters
 - 10.1.1 Large Global Patient Pool
 - 10.1.2 Severity of the Disease
 - 10.1.3 Side Effects of the Existing Drugs
 - 10.1.4 Unmet Requirement of Completely Curative Agents
- 10.2 Major Challenges of Cancer Angiogenesis Inhibitors Market
 - 10.2.1 Difficulties Associated with Evaluation of Anti Angiogenic Effect of Drugs

- 10.2.2 Prospects of Delayed Toxicity with Long-Term Anti-Angiogenic Therapy
- 10.2.3 Need of the Better Therapy Models
- 10.2.4 Approval from Regulatory Guidelines: A Major Challenge
- 10.2.5 Journey of Drug from Bench to Bedside: A Matter of Money & Time

11. CONCLUDING REMARKS & FUTURE MARKET PROSPECTS

12. GLOBAL CANCER ANGIOGENESIS INHIBITORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

- 12.1 Unknown
- 12.2 Research
- 12.3 Preclinical
- 12.4 Clinical
- 12.5 Phase-I
- 12.6 Phase-I/II
- 12.7 Phase-II
- 12.8 Phase-II/III
- 12.9 Phase-III
- 12.10 Preregistration

13. MARKETED CANCER ANGIOGENESIS INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION

- 13.1 Apatinib
- 13.2 Lenalidomide (Ladevina & Revlimid)
- 13.3 Pomalidomide (Imnovid & Pomalyst)
- 13.4 Sorafenib (Nexavar)
- 13.5 Thalidomide (Thaled, Thalidomide Celgene & Thalomid)
- 13.6 Pazopanib (Votrient)
- 13.7 Bevacizumab (Avastin)
- 13.8 Bevacizumab Biosimilar (Cizumab)
- 13.9 Cetuximab (Erbix)
- 13.10 Axitinib (Inlyta)
- 13.11 Recombinant Human Endostatin (Endostar & Endu)

14. DISCONTINUED & SUSPENDED CANCER ANGIOGENESIS INHIBITORS CLINICAL PIPELINE BY COMPANY & PHASE

14.1 No Development Reported

14.2 Discontinued

14.3 Suspended

15. COMPETITIVE LANDSCAPE

15.1 Advenchen Laboratories

15.2 Allergan

15.3 Alnylam Pharmaceuticals

15.4 Amgen

15.5 Angstrom Pharmaceuticals

15.6 Acceleron Pharma

15.7 Biocon

15.8 Bionomics

15.9 CASI Pharmaceuticals

15.10 Celgene Corporation

15.11 Enzon Pharmaceuticals

15.12 Five Prime Therapeutics

15.13 Fujifilm Kyowa Kirin Biologics

15.14 Genentech

15.15 Genexine

15.16 Hetero Drugs

15.17 ImClone Systems

15.18 Intas Pharmaceuticals

15.19 Kyowa Hakko Kirin

15.20 Levolta Pharmaceuticals

15.21 Mabtech

15.22 Marsala Biotech

15.23 Neumedicines

15.24 Novartis

15.25 Oncobiologics

15.26 Onyx Pharmaceuticals

15.27 Pfizer

15.28 Philogen

15.29 TBG Diagnostics

15.30 Reliance Life Sciences

15.31 Roche

15.32 Samsung Bioepis

15.33 Simcere Pharmaceutical Group

- 15.34 SynCore Biotechnology
- 15.35 TaiRx
- 15.36 Taiwan Liposome Company
- 15.37 Tiltan Pharma
- 15.38 XBiotech

List Of Figures

LIST OF FIGURES

Figure 3-1: Different Stages of Involved in Angiogenesis

Figure 3-2: Different Types of Angiogenesis

Figure 3-3: Steps Involved in Sprouting Angiogenesis

Figure 3-4: Steps Involved in Splitting Angiogenesis

Figure 4-1: Different Types of Modulators of Angiogenesis

Figure 4-2: Pathway Followed by VEGF during Angiogenesis

Figure 4-3: Modulatory Pathway of FGF in Angiogenesis

Figure 4-4: Basic Pathway Followed by Modulators to Facilitate Angiogenesis

Figure 5-1: Mechanism of Angiogenesis Stimulated by Tumor Cells

Figure 6-1: Various Categories of Angiogenesis Inhibitors

Figure 8-1: Important Applications of Angiogenic Inhibitors

Figure 9-1: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (%), 2016

Figure 9-2: Global Cancer Angiogenesis Inhibitors Clinical Pipeline by Phase (Numbers), 2016

Figure 9-3: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (%), 2016

Figure 9-4: Global Cancer Angiogenesis Inhibitors Suspended & Discontinued in Clinical Pipeline (Numbers), 2016

Figure 10-1: Favorable Parameters for Cancer Angiogenesis Inhibitors Market

Figure 10-2: Major Challenges of Cancer Angiogenesis Inhibitors Market

Figure 15-1: Advanchen Laboratories - Clinical Pipeline

Figure 15-2: Alexion Pharmaceuticals - Clinical Pipeline

Figure 15-3: Alnylam Pharmaceuticals – Clinical Pipeline

Figure 15-4: Amgen - Clinical Pipeline

Figure 15-5: Acceleron Pharma – Clinical Pipeline

Figure 15-6: Biocon - Clinical Pipeline

Figure 15-7: Bionomics – Clinical Pipeline

Figure 15-8: Casi Pharmaceutical - Clinical Development

Figure 15-9: Celgene - Clinical Pipeline

Figure 15-10: Five Prime Therapeutics – Clinical Pipeline

Figure 15-11: Fujifilm Kyowa Kirin Biologics - Clinical Pipeline

Figure 15-12: Genexine - Clinical Pipeline

Figure 15-13: Levolta Pharmaceuticals – Clinical Pipeline

Figure 15-14: Neumedicines - Clinical Pipeline

Figure 15-15: Novartis - Clinical Pipeline

Figure 15-16: Oncobiologics - Clinical Pipeline

Figure 15-17: Philogen – Clinical Pipeline

Figure 15-18: Samsung Bioepis - Clinical Pipeline

Figure 15-19: Sincere Pharmaceutical Group – Clinical Pipeline

Figure 15-20: SynCore Biotechnology – Clinical Pipeline

List Of Tables

LIST OF TABLES

Table 1-1: List of the Major Events in History of Angiogenesis Inhibitors Development

Table 2-1: List of FDA Approved Drugs & Their Target Cancer

Table 4-1: List of Some Angiogenesis Inhibitors & Their Target Receptors

I would like to order

Product name: Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight

Product link: <https://marketpublishers.com/r/GBAF6089CA3EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBAF6089CA3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970